KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Medpace Holdings (MEDP) over the last 10 years, with Sep 2025 value amounting to -$87,000.

  • Medpace Holdings' Gains from Investment Securities fell 70.59% to -$87,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $92.2 million, marking a year-over-year increase of 33.53%. This contributed to the annual value of $83.6 million for FY2024, which is 9.45% up from last year.
  • As of Q3 2025, Medpace Holdings' Gains from Investment Securities stood at -$87,000, which was down 583.33% from $18,000 recorded in Q2 2025.
  • Over the past 5 years, Medpace Holdings' Gains from Investment Securities peaked at $91.7 million during Q4 2024, and registered a low of -$8.0 million during Q1 2024.
  • Its 3-year average for Gains from Investment Securities is $14.6 million, with a median of -$51,000 in 2024.
  • As far as peak fluctuations go, Medpace Holdings' Gains from Investment Securities spiked by 130.89% in 2021, and later plummeted by 21,600.00% in 2023.
  • Quarterly analysis of 5 years shows Medpace Holdings' Gains from Investment Securities stood at $53.1 million in 2021, then decreased by 9.17% to $48.3 million in 2022, then skyrocketed by 59.85% to $77.2 million in 2023, then grew by 18.86% to $91.7 million in 2024, then slumped by 70.59% to -$87,000 in 2025.
  • Its last three reported values are -$87,000 in Q3 2025, $18,000 for Q2 2025, and $502,000 during Q1 2025.